Hermes Medical Solutions Releases Hybrid Dosimetry™ with
OLINDA / EXM® 2.0 for Personalized Dosimetry
Stockholm - July 31st 2017
Hybrid Dosimetry™ and OLINDA / EXM® 2.0, now integrated, offers a comprehensive dosimetry solution that makes patient imaging easier, more efficient and accurate by eliminating errors associated with manually transferring absorbed dose calculations.
The OLINDA / EXM® 2.0 is a modification of OLINDA / EXM® 1.1 (K033960) and includes new human models and nuclides. OLINDA / EXM® 2.0 employs a new set of decay data recommended by the International Commission on Radiological Protection (ICRP). OLINDA / EXM® 2.0 introduces a new series of anthropomorphic human body models (phantoms), so new values of Specific Absorbed Fractions (SAF) were generated. These phantoms were based on updated values of the mass of the target region recommended by the ICRP.
The intended use of OLINDA / EXM is to provide estimates (deterministic) of absorbed radiation dose at the whole organ level as a result of administering any radionuclide and to calculate effective whole-body dose. This is dependent on input data regarding bio distribution being supplied to the application.
Serial radionuclide imaging provides patient specific information for the individual nuclide kinetics in tumors and normal organs to an administered dose. That allows clinicians to personalize further dose to the patient optimizing patient outcome while reducing costs by. Tailoring personalized Targeted Radionuclide Therapy for Peptide Receptor (PRRT) or prostate cancer to absorbed dose limits, requires dosimetry of the highest accuracy.
Volume delineation of critical organs such as renal cortex, liver, spleen is time consuming when done manually. It has been reported that severe permanent renal toxicity occurs in 9% of cases as late as 1–10 years after PRRT treatment with 90Y-DOTA-octreotide. Hematological toxicity of equivalent severity was also reported in 10 % of patients treated with 177LuDOTA-octreotate*.
The absorbed dose to tumors shows large inter-patient variance and inter-patient variability in kidney dosimetry is too great to justify use of a group-averaged absorbed dose. For patients treated with 177 Lu-DOTA-octreotide, the absorbed dose ranged between 2 and 10 Gy. The absorbed dose to the tumor shows huge inter-patient variance with 177 Lu-DOTA-octreotide and Liver metastases were reported to receive a dose of 167 ± 139 Gy for the ﬁrst treatment cycle with 7.4 GBq*.
The Hybrid Dosimetry™ solution allows for faster clinical throughput, from imaging to performing MIRD absorbed dose calculations and includes:
- Hybrid Dosimetry™ for organ delineation and residence time calculation
- OLINDA / EXM® 2.0 for MIRD based dosimetry
To learn more about the new Hybrid 3D™ and how Hermes is bringing Innovation for Referring Services and Treatment, visit us at booth #2165 during the RSNA meeting November 26th through December 1st 2017.
About Hermes Medical Solutions
Hermes Medical Solutions holds more than 40 years of recognition for Clinical Excellence and innovation in Molecular Imaging. Hermes delivers Enterprise Class systems and software for integrating, visualizing, processing and archiving imaging data from different imaging modalities and devices within Molecular Imaging and Radiology. Hermes solutions are empowering physicians by enabling a faster and more accurate diagnosis of patients, thereby improving quality and efficiency for healthcare provider’s clinical decision making.
Director Strategic Marketing